Who are Ancef In Sodium Chloride 0.9% In Plastic Container's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Maxipime, Vonoprazan+amoxicillin 7 days, Cefepime, Meropenem, or Piperacillin/Tazobactam, Ilaprazole + Amoxicillin, Pivmecillinam/augmentin, Single Agent IV Antibiotic Therapy - MSSA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefazolin-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ancef In Sodium Chloride 0.9% In Plastic Container — Competitive Intelligence Brief

Ancef In Sodium Chloride 0.9% In Plastic Container (Cefazolin Sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin. Area: Metabolic.

marketed Cephalosporin Bacterial cell wall peptidoglycan Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ancef In Sodium Chloride 0.9% In Plastic Container (Cefazolin Sodium) — GSK. Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ancef In Sodium Chloride 0.9% In Plastic Container TARGET	Cefazolin Sodium	GSK	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Maxipime	Cefepime Hydrochloride	Baxter	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Vonoprazan+amoxicillin 7 days	Vonoprazan+amoxicillin 7 days	Xijing Hospital of Digestive Diseases	marketed	Potassium-competitive acid blocker + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Cefepime, Meropenem, or Piperacillin/Tazobactam	Cefepime, Meropenem, or Piperacillin/Tazobactam	University of Florida	marketed	Beta-lactam antibiotic (cephalosporin, carbapenem, or aminopenicillin with beta-lactamase inhibitor)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Ilaprazole + Amoxicillin	Ilaprazole + Amoxicillin	Il-Yang Pharm. Co., Ltd.	marketed	Proton pump inhibitor + Beta-lactam antibiotic combination	H+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin)
Pivmecillinam/augmentin	Pivmecillinam/augmentin	Radboud University Medical Center	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Single Agent IV Antibiotic Therapy - MSSA	Single Agent IV Antibiotic Therapy - MSSA	West Virginia University	marketed	Beta-lactam antibiotic	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cephalosporin class)

Baxter · 1 drug in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ancef In Sodium Chloride 0.9% In Plastic Container — Competitive Intelligence Brief. https://druglandscape.com/ci/cefazolin-sodium. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab